|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Yi-Ning Su | CHIA-CHENG HUNG | CHIA-CHENG HUNG | (02)2382 6615 | 4F.-2, No. 66-1, Sec. 1, Chongqing S. Rd., Zhongzheng Dist.,Taipei City 100, Taiwan (R.O.C.) | 2018/01/22 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | Our medical laboratory at Sofiva Genomics is led by an integrated team of R&D professionals, lab technicians, bioinformatics analysts, database specialists, and clinicians, all working together to promote clinical research and application of genomics within the context of preventative medicine. Our gifted team of R&D and technical specialists are at the forefront, both locally and internationally, of developing diagnostic platforms to read genes associated with spinal muscular atrophy, neonatal sensorineural hearing loss, and congenital central hypoventilation syndrome. Their work also includes testing gene array and conducting preimplantation genetic diagnosis, NGS for PGS, and NIPS+. We have developed customized genetic testing services that allow us to predict and sometimes take early preventative measures against certain health conditions. |
Market Information ( 2024/04/25 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
429.916 | 48.40 | 41.95 | 48.40 | 4.40 | 334 | .00 | N/A | N/A | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/04/25) |
TPEx measures adopted (2024/04/25) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | N | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |